Fintel reports that on November 15, 2024, B of A Securities downgraded their outlook for bluebird bio (MUN:BLE) from Buy to Neutral.
Analyst Price Forecast Suggests 52.97% Downside
As of December 21, 2023, the average one-year price target for bluebird bio is 7,48 €/share. The forecasts range from a low of 3,03 € to a high of 10,50 €. The average price target represents a decrease of 52.97% from its latest reported closing price of 15,90 € / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for bluebird bio is 50MM, a decrease of 5.56%. The projected annual non-GAAP EPS is -11.73.
What is the Fund Sentiment?
There are 271 funds or institutions reporting positions in bluebird bio. This is an decrease of 24 owner(s) or 8.14% in the last quarter. Average portfolio weight of all funds dedicated to BLE is 0.02%, an increase of 7.58%. Total shares owned by institutions decreased in the last three months by 14.73% to 86,320K shares.
What are Other Shareholders Doing?
BlackRock holds 15,444K shares representing 7.96% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 5,862K shares representing 3.02% ownership of the company. In its prior filing, the firm reported owning 6,058K shares , representing a decrease of 3.33%. The firm decreased its portfolio allocation in BLE by 27.64% over the last quarter.
LACAX - Columbia Acorn Fund holds 5,366K shares representing 2.77% ownership of the company. No change in the last quarter.
Geode Capital Management holds 4,683K shares representing 2.42% ownership of the company. In its prior filing, the firm reported owning 4,516K shares , representing an increase of 3.56%. The firm decreased its portfolio allocation in BLE by 49.50% over the last quarter.
IWM - iShares Russell 2000 ETF holds 4,429K shares representing 2.28% ownership of the company. In its prior filing, the firm reported owning 4,660K shares , representing a decrease of 5.21%. The firm decreased its portfolio allocation in BLE by 20.26% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
